Unity Biotechnology
United States
4 articles about Unity Biotechnology
-
UNITY Biotechnology’s lead asset, UBX1325, failed to show non-inferiority to Regeneron’s blockbuster Eylea in a Phase II wet age-related macular degeneration trial.
-
While showing early promise, Senolytics is a new field and most of the research is still in academic centers – most notably, the Mayo Clinic.
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Ghosh succeeds current Unity CEO Keith Leonard, who will step down from his role. Leonard will continue as the chairman of the board of directors.